Growth factors: possible roles for clinical management of the short bowel syndrome

Seminars in Pediatric Surgery

Volumn 19, Issue 1, 2010, Pages 35-43

  McMellen, Mark E ^a   Wakeman, Derek ^a   Longshore, Shannon W ^b   McDuffie, Lucas A ^c   Warner, Brad W ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Eastern Virginia School of Medicine   (United States)

Author keywords

Adaptation; Enterocyte; Growth factor; Mucosa; Proliferation

Indexed keywords

CORTICOSTEROID; EPIDERMAL GROWTH FACTOR; ESTRADIOL; GLUCAGON LIKE PEPTIDE 2; GLUCOCORTICOID; GLUTAMINE; GROWTH HORMONE; LEPTIN; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TEDUGLUTIDE; TESTOSTERONE; THYROXINE;

ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME LOCALIZATION; GROWTH REGULATION; HUMAN; INTESTINE ADAPTATION; LIGAND BINDING; LOW DRUG DOSE; NONHUMAN; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN BINDING; SHORT BOWEL SYNDROME; SMALL INTESTINE RESECTION; TREATMENT OUTCOME;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CELL PROLIFERATION; ENTEROCYTES; EPIDERMAL GROWTH FACTOR; GLUCAGON-LIKE PEPTIDE 2; GROWTH HORMONE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINE, SMALL; PEPTIDE HORMONES; RATS; SHORT BOWEL SYNDROME; SOMATOMEDINS;

EID: 72549113020     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2009.11.010     Document Type: Article

References (114)

1. Warner B.W., and Ziegler M.M. Management of the short bowel syndrome in the pediatric population. Pediatr Clin North Am 40 (1993) 1335-1350
2. Collins J.B., Georgeson K.E., Vicente Y., et al. Short bowel syndrome. Semin Pediatr Surg 4 (1995) 60-72
3. Williamson R.C. Intestinal adaptation (first of two parts). Structural, functional and cytokinetic changes. N Engl J Med 298 (1978) 1393-1402
4. Dowling R.H., and Booth C.C. Structural and functional changes following small intestinal resection in the rat. Clin Sci 32 (1967) 139-149
5. Dowling R.H. Small bowel adaptation and its regulation. Scand J Gastroenterol Suppl 74 (1982) 53-74
6. Messing B., Crenn P., Beau P., et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 117 (1999) 1043-1050
7. Warner B.W., Vanderhoof J.A., and Reyes J.D. What's new in the management of short gut syndrome in children. J Am Coll Surg 190 (2000) 725-736
8. Rosenfeld R.G., and Hwa V. The growth hormone cascade and its role in mammalian growth. Horm Res 71 suppl 2 (2009) 36-40
9. Lichanska A.M., and Waters M.J. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet 24 (2008) 41-47
10. Delehaye-Zervas M.C., Mertani H., Martini J.F., et al. Expression of the growth hormone receptor gene in human digestive tissue. J Clin Endocrinol Metab 78 (1994) 1473-1480
11. Nucci A.M., Finegold D.N., Yaworski J.A., et al. Results of growth trophic therapy in children with short bowel syndrome. J Pediatr Surg 39 (2004) 335-339
12. Zhou X., Li Y.X., Li N., et al. Glutamine enhances the gut-trophic effect of growth hormone in rat after massive small bowel resection. J Surg Res 99 (2001) 47-52
13. Gu Y., Wu Z.H., Xie J.X., et al. Effects of growth hormone (rhGH) and glutamine supplemental parenteral nutrition on intestinal adaptation in short bowel rats. Clin Nutr 20 (2001) 159-166
14. Waitzberg D.L., Cukier C., Mucerino D.R., et al. Small bowel adaptation with growth hormone and glutamine after massive resection of rat's small bowel. Nutr Hosp 14 (1999) 81-90
15. Fadrique B., Lopez J.M., Bermudez R., et al. Growth hormone plus high protein diet promotes adaptation after massive small bowel resection in aged rats. Exp Gerontol 36 (2001) 1727-1737
16. Lund P.K. Molecular basis of intestinal adaptation: the role of the insulin-like growth factor system. Ann N Y Acad Sci 859 (1998) 18-36
17. Seguy D., Vahedi K., Kapel N., et al. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology 124 (2003) 293-302
18. Byrne T.A., Persinger R.L., Young L.S., et al. A new treatment for patients with short-bowel syndrome: growth hormone, glutamine, and a modified diet. Ann Surg 222 (1995) 243-254
19. Scolapio J.S., Camilleri M., Fleming C.R., et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology 113 (1997) 1074-1081
20. Wu G.H., Wu Z.H., and Wu Z.G. Effects of bowel rehabilitation and combined trophic therapy on intestinal adaptation in short bowel patients. World J Gastroenterol 9 (2003) 2601-2604
21. Byrne T.A., Morrissey T.B., Nattakom T.V., et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. J Parenter Enteral Nutr 19 (1995) 296-302
22. Scolapio J.S. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. J Parenter Enteral Nutr 23 (1999) 309-312 discussion: 312-3
23. Ellegard L., Bosaeus I., Nordgren S., et al. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg 225 (1997) 88-96
24. Szkudlarek J., Jeppesen P.B., and Mortensen P.B. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, cross-over, placebo controlled study. Gut 47 (2000) 199-205
25. Weiming Z., Ning L., and Jieshou L. Effect of recombinant human growth hormone and enteral nutrition on short bowel syndrome. J Parenter Enteral Nutr 28 (2004) 377-381
26. de Agustin J.C., Vazquez J.J., Rodriguez-Arnao D., et al. Severe short-bowel syndrome in children: clinical experience. Eur J Pediatr Surg 9 (1999) 236-241
27. Velasco B., Lassaletta L., Gracia R., et al. Intestinal lengthening and growth hormone in extreme short bowel syndrome: a case report. J Pediatr Surg 34 (1999) 1423-1424
28. Ladd A.P., Grosfeld J.L., Pescovitz O.H., et al. The effect of growth hormone supplementation on late nutritional independence in pediatric patients with short bowel syndrome. J Pediatr Surg 40 (2005) 442-445
29. Dahly E., Guo Z., and Ney D.M. IGF-1 augments resection-induced mucosal hyperplasia by altering enterocyte kinetics. Am J Physiol Regul Integr Comp Physiol 285 (2003) R800-R808
30. Ohneda K., Ulshen M.H., Fuller C.R., et al. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 112 (1997) 444-454
31. Winesett D.E., Ulshen M.H., Hoyt E.C., et al. Regulation and localization of the insulin-like growth factor system in small bowel during altered nutrient status. Am J Physiol 268 (1995) G631-G640
32. Vanderhoof J.A., McCusker R.H., Clark R., et al. Truncated and native insulinlike growth factor I enhance mucosal adaptation after jejunoileal resection. Gastroenterology 102 (1992) 1949-1956
33. Gillingham M.B., Dahly E.M., Murali S.G., et al. IGF-1 treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome. Am J Physiol Regul Integr Comp Physiol 284 (2003) R363-R371
34. Knott A.W., Juno R.J., Jarboe M.D., et al. Smooth muscle overexpression of IGF-1 induces a novel adaptive response to small bowel resection. Am J Physiol Gastrointest Liver Physiol 287 (2004) G562-G570
35. Barnham K.J., Torres A.M., Alewood D., et al. Role of the 6-20 disulfide bridge in the structure and activity of epidermal growth factor. Protein Sci 7 (1998) 1738-1749
36. Kumar V., Fausto N., and Abbas A. Robbins and Cotran Pathologic Basis of Disease. 7th edition (2005), Elsevier Saunders, St. Louis, MO
37. Dreux A.C., Lamb D.J., Modjtahedi H., et al. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 186 (2006) 38-53
38. Yates R.A., Nanney L.B., Gates R.E., et al. Epidermal growth factor and related growth factors. Int J Dermatol 30 (1991) 687-694
39. Brown B.W., Mattner P.E., Panaretto B.A., et al. Effect of mouse epidermal growth factor on plasma concentrations of LH, FSH and testosterone in rams. J Reprod Fertil 87 (1989) 649-655
40. Brown G.L., Curtsinger L.J., White M., et al. Acceleration of tensile strength of incisions treated with EGF and TGF-beta. Ann Surg 208 (1988) 788-794
41. Chaet M.S., Arya G., Ziegler M.M., et al. Epidermal growth factor enhances intestinal adaptation after massive small bowel resection. J Pediatr Surg 29 (1994) 1035-1038
42. O'Loughlin E., Winter M., Shun A., et al. Structural and functional adaptation following jejunal resection in rabbits: effect of epidermal growth factor. Gastroenterology 107 (1994) 87-93
43. Lukish J., Schwartz M.Z., Rushin J.M., et al. A comparison of the effect of growth factors on intestinal function and structure in short bowel syndrome. J Pediatr Surg 32 (1997) 1652-1655
44. Fiore N.F., Ledniczky G., Liu Q., et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg 33 (1998) 24-29
45. Iskit S.H., Tugtepe H., Ayyildiz S.H., et al. Epidermal growth factor and bombesin act synergistically to support intestinal adaptation in rats with massive small bowel resection. Pediatr Surg Int 21 (2005) 436-440
46. Helmrath M.A., Erwin C.R., and Warner B.W. A defective EGF-receptor in waved-2 mice attenuates intestinal adaptation. J Surg Res 69 (1997) 76-80
47. Helmrath M.A., Shin C.E., Fox J.W., et al. Adaptation after small bowel resection is attenuated by sialoadenectomy: the role of endogenous epidermal growth factor. Surgery 124 (1998) 848-854
48. Erwin C.R., Helmrath M.A., Shin C.E., et al. Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection. Am J Physiol 277 (1999) G535-G540
49. Stern L.E., Erwin C.R., O'Brien D.P., et al. Epidermal growth factor is critical for intestinal adaptation following small bowel resection. Microsc Res Tech 51 (2000) 1131-1137
50. Shin C.E., Falcone R.A., Duane K.R., et al. The distribution of endogenous epidermal growth factor after small bowel resection suggests increased intestinal utilization during adaptation. J Pediatr Surg 34 (1999) 22-26
51. Knott A.W., Erwin C.R., Profitt S.A., et al. Localization of postresection EGF receptor expression using laser capture microdissection. J Pediatr Surg 38 (2003) 440-445
52. Avissar N.E., Wang H.T., Miller J.H., et al. Epidermal growth factor receptor is increased in rabbit intestinal brush border membrane after small bowel resection. Dig Dis Sci 45 (2000) 1145-1152
53. Barrandon Y., and Green H. Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor. Cell 50 (1987) 1181-1187
54. Shin C.E., Helmrath M.A., Falcone R.A., et al. Epidermal growth factor augments adaptation following small bowel resection: optimal dosage, route and timing of administration. J Surg Res 77 (1998) 11-16
55. Stern L.E., Falcone R.A., Huang F., et al. Epidermal growth factor alters the bax:bcl-w ratio following massive small bowel resection. J Surg Res 91 (2000) 38-42
56. Sheng G., Guo J., and Warner B.W. Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 293 (2007) G599-G606
57. Ryan C.K., Miller J.H., Seydel A.S., et al. Epidermal growth factor and neurotensin induce microvillus hypertrophy following massive enterectomy. J Gastrointest Surg 1 (1997) 467-473
58. Jacobs D.O., Evans D.A., Mealy K., et al. Combined effects of glutamine and epidermal growth factor on the rat intestine. Surgery 104 (1988) 358-364
59. Liu C.D., Rongione A.J., Shin M.S., et al. Epidermal growth factor improves intestinal adaptation during somatostatin administration in vivo. J Surg Res 63 (1996) 163-168
60. Bernal N.P., Stehr W., Profitt S., et al. Combined pharmacotherapy that increases proliferation and decreases apoptosis optimally enhances intestinal adaptation. J Pediatr Surg 41 (2006) 719-724
61. Mayo K.E., Miller L.J., Bataille D., et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55 (2003) 167-194
62. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002) 531-544
63. Munroe D.G., Gupta A.K., Kooshesh F., et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A 96 (1999) 1569-1573
64. Tavares W., Drucker D.J., and Brubaker P.L. Enzymatic- and renal-dependent catabolism of the intestinotrophic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 278 (2000) E134-E139
65. Jeppesen P.B., Sanguinetti E.L., Buchman A., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54 (2005) 1224-1231
66. Yusta B., Huang L., Munroe D., et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119 (2000) 744-755
67. Bjerknes M., and Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A 98 (2001) 12497-12502
68. Orskov C., Hartmann B., Poulen S.S., et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124 (2005) 105-112
69. Roberge J.N., and Brubaker P.L. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128 (1991) 3169-3174
70. Xiao Q., Boushey R.P., Drucker D.J., et al. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117 (1999) 99-105
71. Jeppesen P.B., Hartmann B., Thulesen J., et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 47 (2000) 370-376
72. Jeppesen P.B., Hartmann B., Hansen B.S., et al. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 45 (1999) 559-563
73. Gleeson M.H., Bloom S.R., Polak J.M., et al. An endocrine tumour in kidney affecting small bowel structure, motility, and function. Gut 11 (1970) 1060
74. Bloom S.R., and Polak J.M. The hormonal pattern of intestinal adaptation. A major role for enteroglucagon. Scand J Gastroenterol Suppl 74 (1982) 93-103
75. Drucker D.J., Erlich P., Asa S.L., et al. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93 (1996) 7911-7916
76. Tsai C.H., Hill M., Asa S.L., et al. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice. Am J Physiol 273 (1997) E77-E84
77. Ghatei M.A., Goodlad R.A., Taheri S., et al. Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 4 (2001) 1255-1263
78. Cheeseman C.I., and Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol 271 (1996) G477-G482
79. Wojdemann M., Wettergren A., Hartmann B., et al. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33 (1998) 828-832
80. Wojdemann M., Wettergren A., Hartmann B., et al. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 84 (1999) 2513-2517
81. Breholm L., Hornum M., Henriksen B.M., et al. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 44 (2009) 314-319
82. Topstad D., Martin G., and Sigalet D. Systemic GLP-2 levels do not limit adaptation after distal intestinal resection. J Pediatr Surg 3 (2001) 750-754
83. Thulesen J., Hartmann B., Kissow H., et al. Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal-jejunal transposition or small bowel resection. Dig Dis Sci 46 (2001) 379-388
84. Washizawa N., Gu L.H., Gu L., et al. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. J Parenter Enteral Nutr 28 (2004) 399-409
85. Martin G.R., Wallace L.E., Hartmann B., et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 288 (2005) G431-G438
86. Sigalet D.L., Bawazir O., Martin G.R., et al. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum. Dig Dis Sci 51 (2006) 1557-1566
87. Martin G.R., Wallace L.E., and Sigalet D.L. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 286 (2004) G964-G972
88. Garrison A.P., Dekaney C.M., von A., et al. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol 296 (2009) G43-G50
89. Pereira-Fantini P.M., Nagy E.S., Thomas S.L., et al. GLP-2 administration results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. J Pediatr Gastroenterol Nutr 46 (2008) 20-28
90. Sigalet D.L., Wallace L.E., Holst J.J., et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 293 (2007) G211-G221
91. Booth C., Booth D., Williamson S., et al. Teduglutide ([Gly2]GLP-2) protects small intestine stem cells from radiation damage. Cell Prolif 37 (2004) 385-400
92. Zhang W., Zhu W., Zhang J., et al. Protective effects of glucagon-like peptide 2 on intestinal ischemia-reperfusion rats. Microsurgery 28 (2008) 285-290
93. Scott R.B., Kirk D., MacNaughton W.K., et al. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 275 (1998) G911-G921
94. Haderslev K.V., Jeppesen P.B., Hartmann B., et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 37 (2002) 392-398
95. Jeppesen P.B., Hartmann B., Thulesen J., et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120 (2001) 806-815
96. Hartmann B., Harr M.B., Jeppesen P.B., et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85 (2000) 2884-2888
97. Metcalfe A.J., Oliver S.D., Dietrich J., et al. An evaluation of single dose administration of ALX-0600, a GLP-2 analog, in healthy male subjects (abstract 4973). Gastroenterolgy 118 4 suppl 2 pt 2 (2000) A1072
98. Marier J.F., Beliveau M., Mouksassi M.S., et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 48 (2008) 1289-1299
99. Jeppesen PB, Lund P, Gottschalack IB, et al. Short bowel patients treated for two years with glucagon-like peptides 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol Res Pract (in press).
100. O'Keefe S.J., Gliroy R., Jeppesen P.B., et al. Teduglutide, a novel GLP-2 analog, in the management of short bowel syndrome (SBS) patients dependent on parenteral nutrition: a multicenter, multinational placebo-controlled clinical trial. Gastroenterol 134 4 suppl 1 (2008) A-37
101. th annual meeting of the European Society for Clinical Nutrition and Metabolism, Florence, Italy, September 13-16, 2008.
102. Li S., and Rosen J.M. Glucocorticoid regulation of rat whey acidic protein gene expression involves hormone-induced alterations of chromatin structure in the distal promoter region. Mol Endocrinol 8 (1994) 1328-1335
103. Michel M.C., Knapp J., and Ratjen H. Sensitization by dexamethasone of lymphocyte cyclic AMP formation: evidence for increased function of the adenylyl cyclase catalyst. Br J Pharmacol 113 (1994) 240-246
104. Lange C.A. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word?. Mol Endocrinol 18 (2004) 269-278
105. Drozdowski L., and Thomson A.B. Intestinal hormones and growth factors: effects on the small intestine. World J Gastroenterol 15 (2009) 385-406
106. Martiìn del Olmo J.C., del Clement R.J., and Diez G.M. [Behavior of thyroid function following massive intestinal resection. Experimental study]. Nutr Hosp 6 (1991) 227-234
107. Yuksel O., Tatlicioglu E., Poyraz A., et al. Effects of thyroid hormone on the adaptation in short bowel syndrome. J Surg Res 155 (2009) 116-124
108. Kiely J.M., Noh J.H., Pitt H.A., et al. Impaired intestinal cell proliferation and cell death in leptin-deficient obese mice. J Parenter Enteral Nutr 29 (2005) 30-35
109. Sukhotnik I., Vadasz Z., Coran A.G., et al. Effect of leptin on intestinal re-growth following massive small bowel resection in rat. Pediatr Surg Int 22 (2006) 9-15
110. Sukhotnik I., Shiloni E., Mogilner J., et al. Effect of sex and sex hormones on structural intestinal adaptation after massive small bowel resection in rats. J Pediatr Surg 40 (2005) 489-495
111. Schalamon J., Mayr J.M., and Hollwarth M.E. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol 17 (2003) 931-942
112. Spencer A.U., Kovacevich D., McKinney-Barnett M., et al. Pediatric short-bowel syndrome: the cost of comprehensive care. Am J Clin Nutr 88 (2008) 1552-1559
113. Howard L., Ament M., Fleming C.R., et al. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology 109 (1995) 355-365
114. Howard L., Heaphey L., Fleming C.R., et al. Four years of North American registry home parenteral nutrition outcome data and their implications for patient management. J Parenter Enter Nutr 15 (1991) 384-393